Roddy MG, Glazier SS, Agrawal D. Pediatric mastoiditis in the pneumococcal conjugate vaccine era: symptom duration guides empiric antimicrobial therapy. Pediatr Emerg Care. 2007;23(11):779–84.PubMed

Broides A, Dagan R, Greenberg D, Givon-Lavi N, Leibovitz E. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. Clin Infect Dis. 2009;49:1641–7.PubMed

Ruohola A, Meurman O, Nikkari S, Skottman T, Heikkinen T, Ruuskanen O. The dynamics of bacteria in the middle ear during the course of acute otitis media with tympanostomy tube otorrhea. Pediatr Infect Dis J. 2007;26:892–6.PubMed

Aguilar L, Alvarado O, Soley C, Abdelnour A, Dagan R, Arguedas A. Microbiology of the middle ear fluid in Costa Rican children between 2002 and 2007. Int J Pediatr Otorhinolaryngol. 2009;73:1407–11.PubMed

Guevara S, Soley C, Arguedas A, Porat N, Dagan R. Seasonal distribution of otitis media pathogens among Costa Rican children. Pediatr Infect Dis J. 2008;27:12–6.PubMed

Lysenko ES, Lijek RS, Brown SP, Weiser JN. Within-host competition drives selection for the capsule virulence determinant of Streptococcus pneumoniae. Curr Biol. 2010;20:1222–6.PubMedCentralPubMed

Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estrolate, triple sulfonamide, ampicillin, erythromycin estolatetriple sulfonamide, and placebo in 280 patients with acute otitis media under two. and one-half years of age. Clin Pediatr (Phila). 1972;11(4):205–14.

Jacobs MR, Bajaksouzian S, Windau A, Good C. Continued emergence of nonvaccine serotypes of Streptococcus pneumoniae in Cleveland. Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; G1G1556.

Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20(2):368–89.PubMedCentralPubMed

Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005–2006 and activity of faropenem. Antimicrob Agents Chemother. 2008;52(7): 2639–43.PubMedCentralPubMed

Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against emerging serotypes of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(6):2716–9.PubMedCentralPubMed

Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther. 2008;6(5):619–35.PubMed

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement [document M100-S18]. Wayne: Clinical and Laboratory Standards, 2008.

Piglansky L, Leibovitz E, Raiz. S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J. 2003;22(5):405–13.PubMed

Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20(9):829–37.PubMed

Hoberman A, Dagan R, Leibovitz E, et al. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J. 2005;24 (6):525–32.PubMed

Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):258–61.